Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.
Dopaminergic agonists have been usually used as adjunctive therapy for the cure of Parkinson's disease (PD). It is generally believed that treatment with these drugs is symptomatic rather then curative and does not stop or delay the progression of neuronal degeneration. However, several DA agonists of the DA D2-receptor family (including D2, D3 and D4-subtypes) have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental PD models. Here we summarize some recent data from our and other groups underlining the wide pharmacological spectrum of DA agonists currently used for treating PD patients. In particular, the mechanism of action of different DA agonists does not appear to be restricted to the stimulation of selective DA receptor subtypes being these drugs endowed with intrinsic, independent, and peculiar antioxidant effects. This activity may represent an additional pharmacological property contributing to their clinical efficacy in PD.
Uberti
Daniela
D
Department of Biomedical Sciences and Biotechnologies, University of Brescia, Viale Europa 11, Brescia, 25124, Italy.
Bianchi
Irene
I
Olivari
Luca
L
Ferrari-Toninelli
Giulia
G
Bonini
Sara A
SA
Memo
Maurizio
M
D000818:Animals; D052160:Benzothiazoles / Q000494:pharmacology; D003704:Dementia / Q000188:drug therapy; D018491:Dopamine Agonists / Q000494:pharmacology*; D006801:Humans; D018696:Neuroprotective Agents; D010479:Pergolide / Q000494:pharmacology; D000077487:Pramipexole
D052160:Benzothiazoles; D018491:Dopamine Agonists; D018696:Neuroprotective Agents; D010479:Pergolide; D000077487:Pramipexole